Targeted and immunotherapies comprise two of the most promising and expanding classes
of agents in oncology. This chapter reviews clinical indications for targeted and …

Immune checkpoint inhibitors are a new class of oncologic drugs that act via the inhibition of
checkpoints, thereby unlocking the immune system to attack cancer cells. Their emergence …

With the increasing use of targeted anticancer drugs and immunotherapies, there have been
a substantial number of reports concerning life-threatening severe cutaneous adverse …

Objectives: Numerous dermatological side-effects are reported with the use of targeted
therapies. These adverse events derive from common signaling pathways implicated in …

Zusammenfassung Neue Therapeutika, insbesondere Biologika, gehen mit einer Reihe von
neuartigen kutanen unerwünschten Arzneimittelwirkungen (UAW) einher. Diese Reaktionen …

Background: Rash is a common adverse event in oncologic drug clinical trials often leading
to medication discontinuation. Understanding these events can reduce unnecessary …

Background Target-therapy offers a better efficacy for several cancers, with less toxic
adverse effects, if compared with traditional chemotherapy. However cutaneous …

Chemotherapeutic agents and drugs used for targeted tumor therapy often cause
undesirable side effects of the skin which typically are toxic cutaneous reactions (toxicity …

Cutaneous adverse drug reactions produce a significant clinical, financial, and
psychological burden on our healthcare industry. The importance of considering a drug …

Targeted anticancer therapies are an important weapon in the fight against cancer. Targeted
therapies interfere with specific molecules necessary for tumor growth and cancer …